Cargando…

Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Agents capable of reversing P-glycoprotein-associated multidrug resistance have usually failed to enhance chemotherapy activity in patients with solid tumours. Based on its toxicity profile and experimental potency, dexverapamil, the R-enantiomer of verapamil, is considered to be promising for clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehnert, M., Mross, K., Schueller, J., Thuerlimann, B., Kroeger, N., Kupper, H.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150143/ https://www.ncbi.nlm.nih.gov/pubmed/9569055

Ejemplares similares

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study
por: Serin, D, et al.
Publicado: (2005)

A phase II trial of paclitaxel and epirubicin in advanced breast cancer
por: Rischin, D, et al.
Publicado: (2000)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
por: Cappuzzo, F, et al.
Publicado: (2004)

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
por: Baldini, E, et al.
Publicado: (2004)

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
por: Pacilio, C, et al.
Publicado: (2006)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009)

A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer
por: Lee, Jinsun, et al.
Publicado: (2014)

Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
por: Einbeigi, Z., et al.
Publicado: (2008)

Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
por: Topham, C., et al.
Publicado: (1991)

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
por: Eickhoff, A, et al.
Publicado: (2006)

Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
por: Kin, Takanori, et al.
Publicado: (2020)

Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response
por: Murphy, Caitlin, et al.
Publicado: (2019)

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
por: Conte, P F, et al.
Publicado: (2005)

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
por: Scheithauer, W, et al.
Publicado: (1999)

A phase II study of high dose epirubicin in unresectable non small cell lung cancer.
por: Smit, E. F., et al.
Publicado: (1992)

Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer
por: Müller, Volkmar, et al.
Publicado: (2010)

A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
por: Tarpgaard, Line S., et al.
Publicado: (2016)

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
por: Wang, Chengzheng, et al.
Publicado: (2023)

Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma
por: Kim, Jong Gwang, et al.
Publicado: (2004)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
por: Chen, Jianghao, et al.
Publicado: (2013)

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study
por: Humphreys, A C, et al.
Publicado: (2004)

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
por: Starling, N, et al.
Publicado: (2009)

Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial
por: Futamura, Manabu, et al.
Publicado: (2017)

Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
por: Babu, K. Govind, et al.
Publicado: (2019)

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
por: Gennari, A, et al.
Publicado: (2004)

Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer.
por: Pedrazzoli, P., et al.
Publicado: (1997)

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
por: Kalofonos, Haralabos P., et al.
Publicado: (2004)

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.
por: Hernes, E. H., et al.
Publicado: (1997)

Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer
por: Lalisang, R I, et al.
Publicado: (2000)

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
por: Yao, Xin, et al.
Publicado: (2012)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
por: Evans, T. R., et al.
Publicado: (1996)

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
por: Trudeau, Maureen Elizabeth, et al.
Publicado: (2015)

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial
por: Wachters, F M, et al.
Publicado: (2003)

A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
por: Jones, A. S., et al.
Publicado: (1993)

Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer
por: Schønnemann, K R, et al.
Publicado: (2008)

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
por: Bontenbal, M., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_75hmrlsmfptj8vv3tfojen3m8k